RxDoctor Payments Data

Arslan Johnghar, MD

Cardiovascular Disease · Waterbury, CTNPI 1568755700

Payments from drug & device makers

$3,469in general payments, 2019–2025

Across 58 payments — averaging $59.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$1K
  • Novartis$193
  • Boehringer Ingelheim$137
  • E.r. Squibb & Sons, L.L.C.$97
  • Edwards Lifesciences$82
  • plus $199 from 6 others

What the payments were for

  • Grants$1454%
  • Travel & lodging$1,59346%
  • Food & beverage$1,73150%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,469 in reported general payments places this provider in the 65th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$264,830
Medicare patients
1,520
Services billed
3,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban610$879,444
EntrestoSacubitril/Valsartan177$291,853
XareltoRivaroxaban148$196,646
Repatha SureclickEvolocumab107$118,826
JardianceEmpagliflozin68$94,540
MultaqDronedarone Hcl43$69,510
BrilintaTicagrelor38$46,233
Praluent PenAlirocumab37$29,782
FarxigaDapagliflozin Propanediol15$25,644
VascepaIcosapent Ethyl22$16,549
Metoprolol Succinate654$9,128
EdarbiAzilsartan Medoxomil16$8,128
Ranolazine ErRanolazine84$7,926
Flecainide Acetate108$6,200
Atorvastatin Calcium588$5,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$879,444610 claims
NovartisEntresto$193$291,853177 claims
Johnson & JohnsonXarelto$14$196,646148 claims
Boehringer IngelheimJardiance$137$94,54068 claims
AstraZenecaBrilinta, Farxiga$13$71,87753 claims
Sanofi-aventis U.S. LLCMultaq$23$69,51043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →